Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cenderitide · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Cenderitide | DRUG | Cenderitide is a dual receptor natriuretic peptide. |
| Placebo | DRUG | Placebo control |
Top 20 of 31 competitors
Cenderitide is an investigational small molecule being developed for the treatment of heart failure. It is currently in Phase 2 clinical development and has been studied in patients with stable chronic heart failure, including those with moderate renal impairment.
Cenderitide is being developed by Capricor Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol CAPR. The company is conducting clinical trials to evaluate the safety of Cenderitide in patients with heart failure.
Cenderitide is in Phase 2 clinical development for heart failure. It is an investigational drug and has not been approved by regulatory authorities. Two clinical trials have been completed, both focusing on safety in patients with stable chronic heart failure.
Cenderitide has been studied in two completed clinical trials: NCT02359227, a Phase 2 safety study in stable chronic heart failure with 14 participants, and NCT02603614, a Phase 1/2 safety study in chronic stable heart failure with moderate renal impairment with 8 participants.
Cenderitide is a distinct investigational drug developed by Capricor Therapeutics. No alternative names for Cenderitide have been reported in the clinical trial data. It is being studied specifically for its potential role in treating heart failure.